The third-most common cause of autosomal recessive retinitis pigmentosa (RP) is due to defective cGMP phosphodiesterase-6 (PDE6). Previous work using viral gene therapy on PDE6-mutant mouse models demonstrated photoreceptors can be rescued if administered before degeneration. However, whether visual function can be rescued after degeneration onset has not been addressed. This is a clinically important question, as newly diagnosed patients exhibit considerable loss of rods and cones in their peripheral retinas. We have generated and characterized a tamoxifen inducible Cre-loxP rescue allele, Pde6b
Introduction
Retinitis pigmentosa (RP) is the most common cause of hereditary blindness worldwide Bird, 1995; Klein et al., 1995 Klein et al., , 1999 Hartong et al., 2006) . Early symptoms include night blindness, rod degeneration, and secondary cone death (Curcio et al., 2000; Owsley et al., 2000 Owsley et al., , 2001 Jackson et al., 2002) . The third-most common cause of autosomal recessive RP is due to loss of rod-specific cGMP phosphodiesterase-6 (PDE6; McLaughlin et al., 1993 McLaughlin et al., , 1995 Hanh et al., 1994; Danciger et al., 1995; Dryja and Berson, 1995; Huang et al., 1995; Dryja et al., 1999; Daiger et al., 2007; Dvir et al., 2010) . Several mouse models have been used to study disease progression and develop treatments, including Pde6b rd1 , Pde6b rd10 , and Pde6b H620Q (Chang et al., 2002; Hart et al., 2005; Gargini et al., 2007) . Recent progress using gene therapy in treating PDE6 deficiency has been encouraging (Pang et al., 2008; Allocca et al., 2011; Petit et al., 2012) , especially using a newly developed adenoassociated virus (AAV)8 vector (Petrs-Silva et al., 2009; Pang et al., 2011; Wert et al., 2013) .
For several practical reasons, mouse gene therapy is typically conducted by subretinal injection of virus before degeneration. First, efficacy is greatest in mice that do not exhibit early and rapid photoreceptor death. Second, newborns are typically treated because cryoanesthesia, a safer alternative, can be applied (Silva and Gras, 1979; Hirate et al., 1984; Suckow et al., 2012) . Third, maturation of the subretinal extracellular matrix can create a barrier to viral spread (Tawara et al., 1989; Blanks et al., 1993; Gruter et al., 2005) . As a result, the procedure is technically challenging, can cause trauma, can produce large variance in rescue, and can complicate postdegeneration retinal rewiring (Gargini et al., 2007) . Because of these limitations, past experiments have not addressed the clinically important question of whether retinas with grossly advanced disease are treatable. When RP patients are diagnosed, they have midstage disease with peripheral vision loss, and eventually lose central vision, as a result of macular cone degeneration (Tsui et al., 2007; Mitamura et al., 2012) . This is particularly important, as a recent report on human gene therapy indicates that despite functional rescue, photoreceptor degeneration continues to progress (Cideciyan et al., 2013) .
Previous work involved rescuing before degeneration onset in Pde6 mutant mice Tosi et al., 2011a,b; Wert et al., 2013) . To explore the limits of rescue after degeneration, we generated a model that provides control over the timing of intervention and avoids drawbacks inherent with viral transduction. We have now have tested a novel reversible allele, Pde6b
Stop , which, in combination with tamoxifen-inducible Cre recombinase (CreERT2), allows us to control when and where rescue occurs. CreERT2 nuclear translocation induces recombination of loxP sites flanking a transcription/translation-inhibitor signal sequences (Stop). When combined with a Rosa26
CreERT2 driver, and exposed to tamoxifen during early embryogenesis, mutant mice exhibited stable long-term rescue. In contrast, tamoxifen exposure later produced either partial long-term or transient rescue.
Materials and Methods

Mouse lines and husbandry. Pde6b
H620Q mice were derived by oviduct transfer from morulae provided by the European Mouse Mutant Archive (Hart et al., 2005; . Pde6b
Stop mice were generated as described below. . To block Pde6b expression, a floxed Stop cassette was inserted into a nonconserved region of Pde6b intron 1 (Lakso et al., 1992) . The cassette also contains Pgk-Neo for positive selection. To increase the efficiency of generating a correctly targeted, a diphtheria toxin A-chain (DTA) negative selection cassette was added ϳ2 kb downstream of the Stop cassette, within the short right homology arm (McCarrick et al., 1993) . Within the vector, the DTA cassette replaced ϳ1 kb of sequence, which was used as probe for Southern blot screening for homologous targeting events. To isolate targeted clones, KV1 ES cells (F1 129XB6) were electroporated with 10 g PacI-linearized targeting vector DNA and plated onto mitomycin-treated, neomycin-resistant mouse embryonic fibroblasts . The medium was changed 24 h after electroporation and 150 mg/ml G418 was added. Ten days later, individual colonies were picked and screened for homologous recombination with the Pde6b locus. Two lines, 2 and 4, were identified and expanded for further analysis. The Pde6b
Stop locus was re-examined by Southern blot analysis and the chromosome content determined by karyotype analysis. CreERT2 tails and retinas after tamoxifen treatment at E12 or P1-P2 (see Materials and Methods). Percentage recombination is expressed as the amplicon ratio: loxP/(loxPϩStop) ϫ100%.
To generate germline chimeras, 10 -15 ES cells from line 2 were microinjected into individual C57BL/6J blastocysts (Tsang et al., 1996) . Eight to 10 injected blastocysts were surgically implanted into the uteri of recipient foster mothers. To obtain germline transmission, male chimeras were crossed to C57BL/6J females, and progeny evaluated for germline transmission of the Pde6b Stop allele. Tamoxifen treatment of mice and detection of recombination. To prepare the solution of 4-OH-tamoxifen (Sigma-Aldrich, H7904), 50 mg of tamoxifen was sonicated in 1.5 ml of sunflower seed oil, aliquoted, and stored at Ϫ80°C. Before use, an aliquot was heated at 60°C in preparation for injection. Plug-dated pregnant females carrying H620Q/Stop; Creϩ and control embryos were injected with 1 mg of tamoxifen, to produce E0 or E12 exposed embryos (Danielian et al., 1998; Badea et al., 2003) . Alternately, H620Q/Stop; Cre/ϩ newborns and controls were injected with ϳ50 g (P1 ϭ single dose) or ϳ100 g (P1-P2 ϭ double dose) tamoxifen. For identification of the H620Q allele in exon 15, forward 5Ј-TGCCACGACATCGACCACCG-3Ј and reverse 5Ј-GCCATCCCTGCCTTCCCTTGG-3Ј were created. To distinguish the Pde6b
Stop , Pde6b loxP , and Pde6b ϩ alleles in intron 1, we use a three-primer assay: PDE6B GT-F 5Ј-TGTGGTGTTGCTCTGCGG TA-3Ј, PDE6B GT-R 5Ј-ACAAACCTGCACAACCTGCA-3Ј, and PGK-R 5Ј-GTCCTGCACGACGCGAGCTG-3Ј.
ERGs. Visual function was evaluated as described previously Wert et al., 2013) . Mice were dark-adapted overnight, manipulations were conducted under dim red light illumination, and recordings were made using Espion ERG Diagnosys equipment (Diagnosys). Adult C57BL/6J control mice were tested at the beginning of each session to ensure equal readouts from the electrodes for both eyes before testing the experimental mice. Pupils were dilated using topical 2.5% phenylephrine hydrochloride and 1% tropicamide. Mice were anesthetized by intraperitoneal injection of 0.1 ml per 10 g body weight of anesthesia (1.0 ml ketamine 100 mg/ml and 0.1 ml xylazine 20 mg/ml in 8.9 ml PBS). Body temperature was maintained at 37°C using a heating pad during the procedure. Handmade electrodes were placed upon the corneas and gonioscopic prism solution (Alcon) was applied to each eye. Both eyes were recorded simultaneously. For rod and mixed rod-cone responses, ERGs for dark-adapted mice were recorded using pulses of 0.001 and 3 cd-s/m 2 (white 6500 K), respectively. A total of 20 responses were averaged for each trial. For photopic responses, mice were light adapted in the Ganzfeld dome for at least 10 min. A rod-suppressing steady background of 30 cd/m 2 (white 6500K) was continuously present throughout the trials. ERGs were recorded using pulses of 30 cd-s/m 2 (xenon). A total of 20 responses (filtered from 0.03-300 Hz) were averaged for each trial.
Histochemical analyses. Mice were killed and eyes enucleated as described previously Wert et al., 2013) . Hematoxylin and eosin (H&E) retinal sections were prepared by Excalibur Pathology. Quantification of photoreceptor nuclei was conducted on several sections that contained the optic nerve, as follows: the distance between the optic nerve and ciliary body was divided into four quadrants. Three columns of nuclei were counted within each single quadrant. Averages and SDs were calculated from animals for each time-point. Sectioning proceeded along the long axis of the segment so that each section contained upper and lower retina as well as the posterior pole. Whole retina flat-mount analysis. Mice were euthanized according to established Institutional Animal Care and Use Committee guidelines. Eyes were enucleated and placed in 2% paraformaldehyde for 1 h at room temperature. The optic nerve, cornea, and lens were removed. The whole eyecup was then flattened by means of four radial cuts extending out from the optic nerve and mounted with mounting medium (Vectashield, Vector Laboratories). Peanut agglutinin-conjugated Alexa488 staining was accomplished according to the manufacturers instruction (Invitrogen). Visualization was achieved by fluorescence microscopy, and bright-field imaging was used to visualize the whole retina (Leica DM 5000B microscope). Pictures were taken using the Leica Application Suite Software (Leica Microsystems).
Fundus autofluorescence. Imaging was obtained with the Spectralis Scanning Laser Confocal Ophthalmoscope (Heidelberg Engineering). Pupils were dilated, lubricant (GenTeal Liquid Gel, Novartis) was applied to the cornea and body temperature was maintained. The fundus was illuminated with argon laser light (488 nm) and viewing fluorescence through a bandpass filter with a short wavelength cutoff (495 nm). Detector sensitivity was set between 80 and 100 to avoid pixel saturation. Nine successive frames were acquired in high-speed mode (8.9 images/s) and a 55°field, and frames were aligned, averaged, and saved in non-normalized mode (Sparrow et al., 2013) .
Figure 2. Examples of ERG traces from control and experimental Pde6b
H620Q /Pde6b Stop mice at 18 weeks. Scotopic rod-specific (rod) and mixed rod-cone (mixed), and photopic cone (cone) responses (green traces). Top panels, blue arrows indicate b-wave peaks, whereas the red arrow indicates an a-wave peak, which is also shown as tick marks. Average peak values were calculated for eye on each mouse as a function of age and combined into the graph shown in Figure 3 .
Results
Generation of a Pde6b
Stop allele and Pde6b H620 /Pde6b Stop mice We designed a gene targeting vector by BAC recombineering using genomic clone RP23 131C17, which contains Pde6b exons 1 and 2 (Fig. 1A) . The floxed Stop cassette contains multiple polyadenylation signals in all three reading frames and is designed to prevent gene expression. Cre recombinase activity promotes removal of the cassette and restoration of expression (Lakso et al., 1992) . Targeting of Pde6b intron 1 was confirmed by Southern blot analysis using a 3Ј genomic probe (Fig. 1A) and identified two independent ES cell lines: lines 2 and 4 (Fig. 1B) .
We then generated Stop mice. H620Q is a partial loss-offunction missense Pde6b allele that, in homozygotes, results in severely reduced PDE6␤ expression and PDE6-specific activity. This leads to rod degeneration that is less severe than in Pde6b rd1 mice, but comparable to Pde6b rd10 mice (Chang et al., 2002; Hart et al., 2005; Gargini et al., 2007; . A combination of PCR and DNA sequence analyses were used to distinguish wild-type, Pde6b
H620Q
, and Pde6b
Stop alleles during backcrosses and intercrosses (Fig. 1C) (Fig. 4) . By 18 weeks, only 1-2 nuclei remain in Pde6b H620Q /Pde6b Stop mutants, likely comprising cones, as demonstrated by peanut agglutinin staining (PNA; Fig. 5B ).
Early Stop allele recombination results in full restoration of retinal function
By using a conditionally active tamoxifen-inducible CreERT2 (Danielian et al., 1998), we have control over the timing of recombination (Brocard et al., 1997; Kellendonk et al., 1999) and can, in principle, restore Pde6b expression before or after onset of photoreceptor degeneration. To determine whether removal of the Pde6b Stop cassette can reverse the phenotypic effects of Pde6b Stop , we induced Cre recombinase activity during early embryogenesis. The expression driver Rosa26
CreERT2 was used as it expresses Cre recombinase widely in many tissues during embryogenesis and into postnatal development (Hameyer et al., 2007 (Fig. 4) .
Varied phenotypic rescue effects after Stop recombination at midembryogenesis or postnatally
To extend our findings, we analyzed the effects of inducing Stop cassette recombination either during mid-embryogenesis (embryonic day 12.5, E12) or postnatally (postnatal day 1, P1 Table 1. responses were similar to positive control H620Q/ϩ; Rosa26
CreERT2 /ϩ and E0 mice (Fig. 3 , compare E12 black to control blue or E0 green lines). Although mixed rod-cone a-wave peaks did not reach positive control levels, these were higher than mutant controls. Finally, there were no signs of progressive degradation of retinal function between 6 and 18 weeks.
In contrast, a single dose of tamoxifen treatment at P1 failed to produce the strong rescue effects seen at early treatment times (Figs. 2 and 3, P1 orange lines). Although expressed widely in early embryogenesis, the Rosa26-CreERT2 driver may not be active in the postnatal retina (Hameyer et al., 2007) . To determine whether the initial test using a single tamoxifen dose was limiting, we provided newborns with a double tamoxifen dose (P1-P2). PCR analysis of retina DNA from E12 (n ϭ 6) and P1-P2 (n ϭ 3) mice was conducted and detected Stop to loxP alleles recombination occurring at average frequencies of at 39% and 56%, respectively, suggesting Cre recombinase is actively expressed in retinas (Fig. 1D) . To confirm, we monitored photoreceptor function in P1-P2 H620Q/Stop; Creϩ mice and found scotopic rod and maximum a-wave responses were significantly greater in P1-P2 mice D) , and experimental E0, E12, or P1 mice (E-H ). All panels are from 18-week-old mice, except D, which is from a 9-week-old mouse. The ONL is indicated with brackets. F, Quantitative analysis of the number of rows of photoreceptor nuclei in histological sections per week. Averages and SDs were calculated from multiple retinas (n is shown above each column). Unpaired two-tailed Student's t tests were performed on mutant control and experimental data. *p Ͻ 0.05, **p Ͻ 0.01, ***p Ͻ 0.001. than mutant or P1 mice (Fig. 3 P1 -P2 brown line; Table 1 ). In addition, the P1-P2 functional responses were similar to E12 treated mice: although rescue was sustained over the 18 weeks, full restoration of retinal function was not obtained as compared with E0 treatment. Together, these results indicate that CreERT2 recombinase can be activated in the embryonic retinas and postnatal rod photoreceptors.
Full or partial functional restoration of rod and max responses in E0 or E12 and P1-P2 mice suggests preservation of photoreceptors numbers. Histological analysis of E0 mice and control mice showed similar numbers of photoreceptors at ϾP18 of age (8.6 Ϯ 1.5 and 9.5 Ϯ 1.6, respectively; Fig. 4 ). In contrast, both E12 and P1 mice showed a decrease in photoreceptors leading up to week 18 (Fig. 4) . E12 mice showed a suggestion of rescue on photoreceptors at P18 (E12: 4.0 Ϯ 1.6 vs mutant 1.8 Ϯ 0.81, p ϭ 0.054), whereas P1 cell numbers were similar to mutants at P18 (P1: 1.9 Ϯ 0.83 vs mutant 1.8 Ϯ 0.81, p ϭ 0.76). In contrast, partial rescue of photoreceptors was observed in P1-P2 mice (4.2 Ϯ 1.1 vs 1.8 Ϯ 0.81, p ϭ 0.007). Because rods die earlier than cones in Pde6b mutants, most of the missing photoreceptors are not likely to be cones, as demonstrated by detection of similar numbers of PNA-stained cones in all samples at 18 weeks (Fig. 5) . Despite the loss of rods, those remaining are clearly functional in E12 and P1-P2 mice, compared rods in P1 mice ( Fig. 3; Table 1 ).
During the PNA staining analysis, we noted differences in the appearance of the cones between experimental and control samples. Comparison of positive and mutant control flat mounts demonstrated an abnormal PNA staining in the mutant retinas (Fig. 5 A, B) . Instead of small, round punctate shape (Fig. 5A,  inset) , mutant control cones showed a distinct trailing edge/ringshaped shape, reminiscent of a flame (Fig. 5B, inset) . Unexpectedly, we observed the E12 PNA-staining pattern to consist of a mix of clustered groups of either small cones or flame-like cones (Fig. 5C, inset) . In addition, abnormal E12 cones appeared smaller than abnormal cones in the mutant controls. The differences between E12 and mutant control cones cannot be explained by the presence of Cre or tamoxifen treatment, as P1 experimental samples showed a PNA-staining pattern indistinguishable with the mutant controls.
Rescue of an abnormal hyper-autofluorescent fundus pattern
We examined control and experimental retinas by fundus autofluorescence, which detects accumulations in A2E fluorophores in the retina. Wild-type and positive control H620Q/ϩ; Creϩ mice showed a diffuse, homogeneous fluorescence pattern (Fig.   6 A, B) . In contrast, at 9 weeks, mutant control H620Q/Stop mice showed small hyper-autofluorescence (hyper-AF) spots distributed with regular uniformity over the fundus (Fig. 6C) . At 18 weeks, this pattern resolves into a confluence of hyper-AF patches of heterogeneous size (Fig. 6D) . Because hyper-AF is a secondary consequence of photoreceptor degeneration (Robson et al., 2008; Xu et al., 2008; Lima et al., 2009 Lima et al., , 2012 Greenstein et al., 2012) , we expected to observe rescue of the mutant hyper-AF pattern after Stop recombination. Indeed, 18-week-old E0 experimental animals showed a similar pattern as positive control mice with no detectable hyper-AF spots (Fig. 6E) . In contrast, 18-week-old E12 and P1-P2 mice demonstrated hyper-AF pattern similar to the 9-week old mutant controls, but with spots of heterogeneous size and nonuniform distribution (Fig. 6 F, H ) . P1 mice exhibited a fluorescence pattern similar to the mutant controls (Fig. 6G) .
Rescue of arteriolar attenuation
Wild-type and positive control H620Q/ϩ; Creϩ mice showed vessels of normal caliber (Fig. 6 A, B) . Mutant control H620Q/ Stop mice demonstrated arteriolar narrowing, which progressively worsened between 9 and 18 weeks (Fig. 6C,D) . Whereas 18-weekold E0 experimental animals exhibited a similar vessel dimension as positive controls (Fig. 6E) , 18-week-old E12 and P1-P2 mice demonstrated partial arteriolar attenuation similar to the 9-week-old mutants (Fig. 6F,H) , and single dosing at P1 did not rescue arteriolar attenuation (Fig. 6G ).
Discussion
We have tested a novel reversible allele, Pde6b
Stop , which in combination with tamoxifen-inducible Cre, allows us to control photoreceptor rescue without surgical trauma associated with delivery of viral gene therapy vectors. We have shown that untreated Pde6b
H620Q
/Pde6b
Stop mice exhibit a photoreceptor degen- , D) , and experimental E0, E12, P1, or P1-P2 mice (E-H ). All panels are from 18-weekold mice, except C, which is from a 9-week-old mouse. eration phenotype that is slower than Pde6b H620Q homozygous mice (Hart et al., 2005; (Hart et al., 2005) . The slower rate of degeneration exhibited by Pde6b H620Q /Pde6b Stop suggests some transcriptional readthrough events (Miyoshi and Fishell, 2006) . Nevertheless, Pde6b H620Q /Pde6b Stop mice exhibit classic rod and subsequent cone degeneration phenotype as seen in other Pde6b mutant lines (Chang et al., 2002; Hart et al., 2005; Gargini et al., 2007) . As Pde6b H620Q and Pde6b Stop mutations were generated independently, it is unlikely the phenotypes presented here are the result homozygosity at another locus.
This new Pde6b H620Q /Pde6b Stop mouse provides several advantages. First, as a compound heterozygote, the mouse more closely resembles sporadic human cases (McLaughlin et al., 1993 (McLaughlin et al., , 1995 Danciger et al., 1995; . Second, it provides a precise, highly reproducible method for generating "optimally" treated retinas, without the limitations inherent in the use of randomly integrated transgenes or subretinal trauma caused by injection of viral vectors (Deyle and Russell, 2009; Huang and Yang, 2009; Zinkernagel et al., 2011; Biasco et al., 2012; Wert et al., 2012) . Third, this tool is flexible: the Stop mouse can be combined with any CreERT2 driver to readily generate retinas with specific temporal and/or special patterns of degeneration. Cre-ERT2 is recommended, as constitutively active Cre is associated with toxicity (Hameyer et al., 2007) .
Here we used the Rosa26 CreERT2 driver to induce recombination in early embryonic cells and generated efficient rescue. At later times, the ability to rescue photoreceptors is incomplete, likely due to downregulation of the Rosa26 locus in the adult neural lineage (Hameyer et al., 2007) . Nevertheless, Cre activity was detected in retinal photoreceptors after a double-tamoxifen treatment at P1, as demonstrated by restoration of rod photoreceptor function and Stop to-loxP allele recombination in retinal DNA. Although more efficient postnatal photoreceptor-specific CreERT2 drivers are not currently available, one can conceive of using Pde6g
CreERT2 or tetracycline-inducible photoreceptor drivers (Chang et al., 2000) for the purpose of fully exploiting the utility of the Pde6b Stop allele. These types of drivers will be critical for extending the study of treatments beyond early postnatal life and deeper into periods with significant degeneration, which will be the usual clinical setting for patients with RP. The stage of human RP disease that was modeled using the Rosa26 CreERT2 driver in this paper might represent the earliest possible intervention, most likely in young children, after fetal or postnatal genotyping (Kitzman et al., 2012) .
Our mouse model, although not addressing the effects of surgically delivered viral vectors, does suggest two issues inherent in genetic treatment of RP. First, to provide effective gene therapy to patients, it is not clear how many macular rods have to be successfully transduced with PDE6-expressing vectors to prevent secondary loss of cones. Our results suggest that complete, partial, and incomplete restoration of retinal function depend on the number of treated photoreceptors. Not achieving a minimum number of rescued rods is likely to cause nonautonomous death of rescued rods (Kedzierski et al., 1998; Streichert et al., 1999; Delyfer et al., 2005) . Because many RP patients initially present with considerable degeneration (loss of peripheral rods and cones, cases may involve of the macula as well), then early treatment may produce favorable outcomes.
Second, it is not clear which clinical parameters are most important in defining an effective treatment. Our results suggest that, even in cases of long-term functional rescue, retinal pathology may persist after treatment. Although mid-embryonic and postnatal treatment produced long-term rescue of most retinal function, we observed reductions in mixed rod-cone ERG responses, loss of photoreceptors, abnormal cone morphology, and hyper-AF spots. The significance of abnormal cone morphology is not clear, as cone amplitudes appear to be unaffected. However, partial loss of photoreceptors likely contributed to reduced mixed responses and hyper-AF, which may correspond to lysosome-laden microglial cells located between the neural retina and the retinal pigment epithelium (RPE) or abnormal accumulation of lipofuscin in the RPE (Robson et al., 2008; Xu et al., 2008; Lima et al., 2009 Lima et al., , 2012 Wang et al., 2009; Greenstein et al., 2012) . AF spots are not specific to Pde6b model . With a different team of coauthors, we have a manuscript in press (Wang et al., 2013) , we demonstrated that AF spots are microglial rather than of RPE origin. We imagine inefficiencies associated with subretinal surgery, viral immunogenicity, viral transduction, nonendogenous rescue gene expression, and potential vector inactivation/silencing further complicate the picture. Thus, the limits of rescue and the persistence of disease features require future investigation.
Although much progress has been made toward conducting human gene therapy for RP, it is important to continue to define emerging challenges (Stieger and Lorenz, 2010; Sahni et al., 2011) . Indeed, the most recent report on human gene therapy indicates, despite functional rescue, photoreceptor degeneration continues to progress (Cideciyan et al., 2013) . A common denominator to previous successes in modeling gene therapy in PDE6-deficient animals suggests earlier treatment in humans might be effective. However, early identification of sporadic cases may require pediatric screening or sequencing RP genes in fetal DNA in maternal blood (Kitzman et al., 2012) . On the other hand, early treatment may further expose the limits of gene therapy, especially if "successfully treated" maculas harbor subtle signs of disease, either coincident or consequent with treatment, which may or may not progress to blindness. Thus, another viable direction may be to use a combination of gene and drug therapies to stop retinal degeneration (Tosi et al., 2011b; Trifunovic et al., 2012) .
